Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Celogics logo — Quality Cells, Quality Research. Providing iPSC differentiat...

Celogics

Quality Cells, Quality Research. Providing iPSC differentiation services for pharmaceutical research

Founded 2021 United States Seattle, United States 3 employees Biotechnology, Manufacturing

General Information

Company Name Celogics
Founded Year 2021
Location United States Seattle, United States
Employees 3
Industries Biotechnology, Manufacturing
Business Model B2B, D2C, E Commerce
Revenue Model Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Celogics. To contact Celogics, visit celogics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Celogics compare?

A PDF of Celogics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Celogics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Celogics

Celogics, founded in 2021, is carving a niche in the biotechnology and manufacturing sectors by pioneering advanced iPSC differentiation services tailored for pharmaceutical research. With the mission of enhancing the quality of human cell culture, Celogics aims to revolutionize research by producing the highest quality iPSC-derived cells, branded under Celo.Cells.

The company is a joint venture between Curi Bio and NEXEL, leveraging this partnership to drive innovation in drug discovery, safety screening, and disease modeling. The establishment of a 22,000 square feet facility marks a significant step toward becoming the premier supplier of functional cell models.

While investment information is currently unavailable, the burgeoning interest in next-generation cell models positions Celogics as a promising opportunity for future investors seeking to impact the evolving landscape of pharmaceutical research.

Business keywords: iPSC differentiation, pharmaceutical research, human cell culture, research-use-only cell products, drug discovery, drug safety screening, disease modeling, iPSC-derived cells, life sciences, functional cell models, Celo.Cells brand, biotechnology joint venture, cell manufacturing, validated data provision, cell model innovation

Services & Products

Custom Cardiomyocytes Development
High-Quality Human iPSC-derived Cell Products
Drug Development Acceleration
Disease Modeling Research

Target Customers

Pharmaceutical Companies Biotech Researchers Medical Research Institutions Disease Modelers

No funding data available for Celogics yet.

Celogics Alternatives & Competitors

View All Alternatives
Celogics vs
Invitrocue
Invitrocue United States

Invitrocue Pte Ltd. | Transforming Bioanalytics

32 employees
Biotechnology, Health Care
Celogics vs
FUJIFILM Biotechnologies
FUJIFILM Biotechnologies United States

Partners for Life, Advancing Tomorrow's Medicines

5920 employees
Biotechnology, Health Care
Celogics vs
Samsung Biologics
Samsung Biologics Korea South

Innovation, passion and an unwavering dedication to find breakthrough solutions in biomedicines.

2398 employees
Biotechnology, Health Care
View all alternatives

FAQ About Celogics

Quality Cells, Quality Research. Providing iPSC differentiation services for pharmaceutical research
Celogics was founded in 2021.
Celogics is headquartered in Seattle, United States.
Celogics operates in Biotechnology and Manufacturing. Its work centres on iPSC differentiation, pharmaceutical research, human cell culture and research-use-only cell products. Its customers include Pharmaceutical Companies, Biotech Researchers and Medical Research Institutions.
Celogics has a B2B, D2C and E Commerce business model. Its revenue comes from Product Sales and Service Fee.
Celogics has approximately 3 employees.
Celogics offers: Custom Cardiomyocytes Development, High-Quality Human iPSC-derived Cell Products, Drug Development Acceleration, Disease Modeling Research.
Top alternatives and competitors to Celogics include Invitrocue, FUJIFILM Biotechnologies, Samsung Biologics, China Regenerative Medicine International, UNIVERCELLS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Celogics and Invitrocue are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Celogics, https://bouncewatch.com/company/celogics, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes